Multidisciplinary consensus committee	E47
Introduction	E48
Methodology	E48
Recommendations
I. Hematuria: Workup, rapid access clinic, timelines, investigations	E48
II. Optimizing outcomes in high-risk non-muscle-invasive bladder cancer (NMIBC)	E51
III. Salvage therapy in NMIBC	E53
IV. Prostatic urethral disease	E56
V. Immediate postoperative intravesical chemotherapy	E57
VI. Surveillance of NMIBC	E58
VII. Perioperative chemotherapy for MBC	E58
VIII. Surgical quality and outcomes	E60
IX. Bladder preservation approaches with focus on trimodal therapy	E62
X. Perioperative management of cystectomy patients	E63
XI. Perioperative stomal teaching and followup	E65
XII. Variant histology	E65
XIII. Surveillance strategies post-radical cystectomy, partial cystectomy, trimodal therapy	E66
XIV. Management of locally advanced/unresectable disease	E67
XV. Pathology reporting and role of re-review (NMIBC, MIBC)	E68
XVI. Different models for multidisciplinary management of bladder cancer and their impact	E69
XVII. Impact of cystectomy provider characteristics: Surgical wait times, volumes, surgeon characteristics	E70
XVIII. Definition of bladder cancer centres of excellence	E71
XIX. Quality indicators in the management of bladder cancer across Canada	E72
References	E73